Immunotherapeutic options on the horizon in breast cancer treatment

Research output: Contribution to journalReview articleAcademicpeer-review

14 Citations (Scopus)

Abstract

It is increasingly acknowledged that breast cancer can be an immunogenic disease. Immunogenicity appears to differ between subtypes. For instance, in triple negative breast cancer (TNBC) and HER2-positive breast cancer tumor infiltrating lymphocytes (TILs) are prognostic and predictive for response to chemotherapy containing anthracyclines, but in other subtypes they are not. Preclinical evidence suggests important immune based mechanisms of conventional chemotherapeutics, in particular anthracyclines. Early clinical studies with monoclonal antibodies targeting programmed death protein 1, programmed death-ligand 1 and cytotoxic T-lymphocyte-associated antigen 4 have shown anti-tumor efficacy. Tumor vaccines designed to increase the body's own anti-tumor immunity have shown an increased anti-tumor immunity, however clinical efficacy has not yet been demonstrated. Novel strategies will likely follow. In light of the increased interest in immune modulation, this review focuses on predictive immune-based biomarkers, immune-mediated effects from conventional therapies, as well as recent results and ongoing studies concerning immunotherapies in breast cancer. (C) 2015 Elsevier Inc. All rights reserved.

Original languageEnglish
Pages (from-to)90-101
Number of pages12
JournalPharmacology & Therapeutics
Volume156
DOIs
Publication statusPublished - Dec-2015

Keywords

  • Breast cancer
  • Immune system
  • Biomarkers
  • Immunotherapies
  • Immune checkpoint blockade
  • Tumor vaccines
  • TUMOR-INFILTRATING LYMPHOCYTES
  • TRIPLE-NEGATIVE BREAST
  • REGULATORY T-CELLS
  • MISMATCH-REPAIR DEFICIENCY
  • NATURAL-KILLER-CELLS
  • METASTATIC BREAST
  • MONOCLONAL-ANTIBODY
  • ANTITUMOR-ACTIVITY
  • IMMUNE-RESPONSES
  • CLINICAL-TRIAL

Cite this